| 1.1 Disability (primary outcome). Studies at low risk of bias |
5 |
5436 |
Std. Mean Difference (IV, Fixed, 95% CI) |
‐0.00 [‐0.05, 0.05] |
| 1.1.1 Fluoxetine |
5 |
5436 |
Std. Mean Difference (IV, Fixed, 95% CI) |
‐0.00 [‐0.05, 0.05] |
| 1.2 Independent on modified Rankin score (mRS 0 to 2) (primary outcome). Studies at low risk of bias |
5 |
5926 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.98 [0.93, 1.03] |
| 1.3 Neurological deficit score (studies at low risk of bias) |
1 |
30 |
Std. Mean Difference (IV, Fixed, 95% CI) |
‐0.39 [‐1.12, 0.33] |
| 1.3.1 Fluoxetine |
1 |
30 |
Std. Mean Difference (IV, Fixed, 95% CI) |
‐0.39 [‐1.12, 0.33] |
| 1.4 Motor deficits (studies at low risk of bias) |
6 |
5518 |
Std. Mean Difference (IV, Fixed, 95% CI) |
0.03 [‐0.02, 0.08] |
| 1.4.1 Fluoxetine |
6 |
5518 |
Std. Mean Difference (IV, Fixed, 95% CI) |
0.03 [‐0.02, 0.08] |
| 1.5 Depression, continuous data (studies at low risk of bias) |
4 |
5356 |
Std. Mean Difference (IV, Fixed, 95% CI) |
‐0.14 [‐0.19, ‐0.08] |
| 1.5.1 Fluoxetine |
4 |
5356 |
Std. Mean Difference (IV, Fixed, 95% CI) |
‐0.14 [‐0.19, ‐0.08] |
| 1.6 Depression, dichotomous data (studies at low risk of bias) |
3 |
5907 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.75 [0.65, 0.86] |
| 1.6.1 Fluoxetine |
3 |
5907 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.75 [0.65, 0.86] |
| 1.7 Death (trials at low risk of bias) |
6 |
6090 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.01 [0.82, 1.24] |
| 1.7.1 Fluoxetine |
6 |
6090 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.01 [0.82, 1.24] |
| 1.8 Seizures (studies at low risk of bias) |
6 |
6080 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.40 [1.00, 1.98] |
| 1.8.1 Fluoxetine |
6 |
6080 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.40 [1.00, 1.98] |
| 1.9 Gastrointestinal side effects (studies at low risk of bias) |
1 |
30 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.71 [0.33, 8.83] |
| 1.9.1 Fluoxetine |
1 |
30 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.71 [0.33, 8.83] |
| 1.10 Bleeding (studies at low risk of bias) |
6 |
6088 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.08 [0.69, 1.70] |
| 1.10.1 Fluoxetine (except for Asadollahi 2018) |
6 |
6088 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.08 [0.69, 1.70] |
| 1.11 Fractures (studies at low risk of only) |
6 |
6080 |
Odds Ratio (M‐H, Fixed, 95% CI) |
2.35 [1.62, 3.41] |
| 1.12 Cognition (trials at low risk of bias) |
4 |
5373 |
Mean Difference (IV, Fixed, 95% CI) |
‐1.22 [‐2.37, ‐0.07] |
| 1.13 Leaving the study before the end of scheduled follow‐up for reasons other than death (trials at low risk of bias) |
6 |
6090 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.57 [1.03, 2.40] |
| 1.13.1 Fluoxetine |
6 |
6090 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.57 [1.03, 2.40] |
| 1.14 Fatigue at end of treatment (studies at low risk of bias only) |
4 |
5524 |
Mean Difference (IV, Fixed, 95% CI) |
‐0.06 [‐1.24, 1.11] |
| 1.15 Quality of life at end of treatment (studies at low risk of bias) |
3 |
5482 |
Mean Difference (IV, Fixed, 95% CI) |
0.00 [‐0.02, 0.02] |
| 1.16 Disability (all studies regardless of risk of bias) |
32 |
7667 |
Std. Mean Difference (IV, Fixed, 95% CI) |
‐0.18 [‐0.23, ‐0.14] |
| 1.16.1 Fluoxetine |
19 |
6590 |
Std. Mean Difference (IV, Fixed, 95% CI) |
‐0.09 [‐0.13, ‐0.04] |
| 1.16.2 Sertraline |
1 |
130 |
Std. Mean Difference (IV, Fixed, 95% CI) |
‐1.38 [‐1.76, ‐0.99] |
| 1.16.3 Paroxetine |
5 |
293 |
Std. Mean Difference (IV, Fixed, 95% CI) |
‐1.29 [‐1.55, ‐1.03] |
| 1.16.4 Citalopram |
5 |
446 |
Std. Mean Difference (IV, Fixed, 95% CI) |
‐0.68 [‐0.88, ‐0.48] |
| 1.16.5 Escitalopram |
2 |
208 |
Std. Mean Difference (IV, Fixed, 95% CI) |
‐0.67 [‐1.00, ‐0.34] |
| 1.17 Independent on modified Rankin score (mRS 0 to 2) (all studies regardless of risk of bias) |
8 |
6792 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.97 [0.93, 1.01] |
| 1.17.1 Fluoxetine |
6 |
6039 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.98 [0.94, 1.03] |
| 1.17.2 Sertraline |
1 |
111 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.00 [0.97, 1.04] |
| 1.17.3 Citalopram |
1 |
642 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.90 [0.82, 0.98] |
